{
    "organizations": [],
    "uuid": "488d324ce84211afcecad98ce6a87988a2f7d87e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-jj-posts-q1-adj-non-gaap-eps-206/brief-jj-posts-q1-adj-non-gaap-eps-2-06-idUSASC09W2N",
    "ord_in_thread": 0,
    "title": "BRIEF-J&J Posts Q1 Adj Non-Gaap EPS $2.06",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17, 2018 / 11:08 AM / Updated 6 minutes ago BRIEF-J&J Posts Q1 Adj Non-Gaap EPS $2.06 Reuters Staff \nApril 17 (Reuters) - Johnson & Johnson: \n* REPORTS 2018 FIRST-QUARTER RESULTS * Q1 SALES $20 BILLION VERSUS I/B/E/S VIEW $19.46 BILLION \n* Q1 EARNINGS PER SHARE VIEW $2.02 — THOMSON REUTERS I/B/E/S \n* REAFFIRMS FY 2018 ADJUSTED EARNINGS PER SHARE VIEW $8.00 TO $8.20 \n* Q1 ADJUSTED NON-GAAP EARNINGS PER SHARE $2.06 EXCLUDING ITEMS * SEES FY 2018 SALES $81 BILLION TO $81.8 BILLION \n* PLANS TO IMPLEMENT ACTIONS ACROSS ITS GLOBAL SUPPLY CHAIN \n* EXCLUDING NET IMPACT OF ACQUISITIONS AND DIVESTITURES, ON AN OPERATIONAL BASIS, WORLDWIDE SALES INCREASED 4.3 PCT IN QUARTER \n* EXPECTS TO RECORD PRE-TAX RESTRUCTURING CHARGES OF APPROXIMATELY $1.9 TO $2.3 BILLION, WHICH WILL BE TREATED AS A SPECIAL ITEM \n* QTRLY WORLDWIDE CONSUMER SALES $3,398 MILLION VERSUS $3,228 MILLION REPORTED LAST YEAR \n* EXPECTS ACTIONS TO GENERATE APPROXIMATELY $0.6 TO $0.8 BILLION IN ANNUAL PRE-TAX COST SAVINGS THAT WILL BE SUBSTANTIALLY DELIVERED BY 2022 \n* QTRLY WORLDWIDE PHARMACEUTICAL SALES $9,844 MILLION VERSUS $8,245 MILLION REPORTED LAST YEAR \n* EXCLUDING NET IMPACT OF ACQUISITIONS AND DIVESTITURES, ON AN OPERATIONAL BASIS, QTRLY DOMESTIC SALES INCREASED 1.3 PCT \n* QTRLY WORLDWIDE MEDICAL DEVICES SALES $6,767 MILLION VERSUS $6,293 MILLION REPORTED LAST YEAR \n* J&J QTRLY WORLDWIDE REMICADE SALES $1,389 MILLION VERSUS $1,672 MILLION REPORTED LAST YEAR \n* EXCLUDING NET IMPACT OF ACQUISITIONS AND DIVESTITURES, ON AN OPERATIONAL BASIS, QTRLY INTERNATIONAL SALES INCREASED 7.6 PCT \n* J&J QTRLY WORLDWIDE INVOKANA/INVOKAMET SALES $248 MILLION VERSUS $284 MILLION REPORTED LAST YEAR \n* EXPECTS SUPPLY CHAIN ACTIONS WILL INCLUDE EXPANDING USE OF STRATEGIC COLLABORATIONS \n* FIRST-QUARTER 2018 NET EARNINGS INCLUDED AFTER-TAX INTANGIBLE AMORTIZATION EXPENSE OF APPROXIMATELY $1.0 BILLION \n* FIRST-QUARTER NET EARNINGS ALSO INCLUDED CHARGE FOR AFTER-TAX SPECIAL ITEMS OF APPROXIMATELY $0.3 BILLION \n* QTRLY WORLDWIDE VELCADE SALES $313 MILLION VERSUS $280 MILLION REPORTED LAST YEAR \n* QTRLY WORLDWIDE ZYTIGA SALES $845 MILLION VERSUS $523 MILLION REPORTED LAST YEAR \n* U.S. TAX LEGISLATION PASSED LAST YEAR IS CREATING OPPORTUNITY TO INVEST MORE THAN $30 BILLION IN RESEARCH AND DEVELOPMENT, CAPITAL INVESTMENTS IN U.S. OVER NEXT 4 YRS \n* IN MEDICAL DEVICES BUSINESSES, “HAVE AREAS OF LEADERSHIP AND CONTINUE TO MAKE INVESTMENTS AND PORTFOLIO CHOICES TO IMPROVE PERFORMANCE” \n* FY2018 EARNINGS PER SHARE VIEW $8.10, REVENUE VIEW $81.13 BILLION — THOMSON REUTERS I/B/E/S \n* DISCUSSIONS REGARDING SPECIFIC FUTURE ACTIONS IN GLOBAL SUPPLY CHAIN ARE ONGOING Source text for Eikon: Further company coverage:",
    "published": "2018-04-17T14:06:00.000+03:00",
    "crawled": "2018-04-17T14:20:05.038+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "j",
        "post",
        "q1",
        "adj",
        "eps",
        "reuters",
        "staff",
        "april",
        "reuters",
        "johnson",
        "johnson",
        "report",
        "result",
        "q1",
        "sale",
        "billion",
        "versus",
        "view",
        "billion",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "reaffirms",
        "fy",
        "adjusted",
        "earnings",
        "per",
        "share",
        "view",
        "q1",
        "adjusted",
        "earnings",
        "per",
        "share",
        "excluding",
        "item",
        "see",
        "fy",
        "sale",
        "billion",
        "billion",
        "plan",
        "implement",
        "action",
        "across",
        "global",
        "supply",
        "chain",
        "excluding",
        "net",
        "impact",
        "acquisition",
        "divestiture",
        "operational",
        "basis",
        "worldwide",
        "sale",
        "increased",
        "pct",
        "quarter",
        "expects",
        "record",
        "restructuring",
        "charge",
        "approximately",
        "billion",
        "treated",
        "special",
        "item",
        "qtrly",
        "worldwide",
        "consumer",
        "sale",
        "million",
        "versus",
        "million",
        "reported",
        "last",
        "year",
        "expects",
        "action",
        "generate",
        "approximately",
        "billion",
        "annual",
        "cost",
        "saving",
        "substantially",
        "delivered",
        "qtrly",
        "worldwide",
        "pharmaceutical",
        "sale",
        "million",
        "versus",
        "million",
        "reported",
        "last",
        "year",
        "excluding",
        "net",
        "impact",
        "acquisition",
        "divestiture",
        "operational",
        "basis",
        "qtrly",
        "domestic",
        "sale",
        "increased",
        "pct",
        "qtrly",
        "worldwide",
        "medical",
        "device",
        "sale",
        "million",
        "versus",
        "million",
        "reported",
        "last",
        "year",
        "j",
        "j",
        "qtrly",
        "worldwide",
        "remicade",
        "sale",
        "million",
        "versus",
        "million",
        "reported",
        "last",
        "year",
        "excluding",
        "net",
        "impact",
        "acquisition",
        "divestiture",
        "operational",
        "basis",
        "qtrly",
        "international",
        "sale",
        "increased",
        "pct",
        "j",
        "j",
        "qtrly",
        "worldwide",
        "sale",
        "million",
        "versus",
        "million",
        "reported",
        "last",
        "year",
        "expects",
        "supply",
        "chain",
        "action",
        "include",
        "expanding",
        "use",
        "strategic",
        "collaboration",
        "net",
        "earnings",
        "included",
        "intangible",
        "amortization",
        "expense",
        "approximately",
        "billion",
        "net",
        "earnings",
        "also",
        "included",
        "charge",
        "special",
        "item",
        "approximately",
        "billion",
        "qtrly",
        "worldwide",
        "velcade",
        "sale",
        "million",
        "versus",
        "million",
        "reported",
        "last",
        "year",
        "qtrly",
        "worldwide",
        "zytiga",
        "sale",
        "million",
        "versus",
        "million",
        "reported",
        "last",
        "year",
        "tax",
        "legislation",
        "passed",
        "last",
        "year",
        "creating",
        "opportunity",
        "invest",
        "billion",
        "research",
        "development",
        "capital",
        "investment",
        "next",
        "yr",
        "medical",
        "device",
        "business",
        "area",
        "leadership",
        "continue",
        "make",
        "investment",
        "portfolio",
        "choice",
        "improve",
        "performance",
        "fy2018",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "billion",
        "thomson",
        "reuters",
        "discussion",
        "regarding",
        "specific",
        "future",
        "action",
        "global",
        "supply",
        "chain",
        "ongoing",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}